STAB2 and Hepatic fibrosis: Stabilin-2, which has been found to reduce the concentration of low-density lipoproteins, the main molecule responsible for atherosclerosis and indirectly liver fibrosis, has been identified as a promising biomarker for liver fibrosis and a potential therapeutic target [13].